A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

UCB Pharma1 site in 1 countryStarted: January 1, 2004Last updated: October 20, 2014

Conditions

Drugs

Trial Snapshot

Phase: Phase 3
Status: Completed
Sponsor: UCB Pharma
Locations: 1

Study Overview Study Design Eligibility Criteria Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Detailed Description

See approved Package Insert for Adverse Event information.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Crossover
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Stable Parkinson's Disease

Exclusion Criteria

•Not using carbidopa/levodopa tablets

Investigators

Sponsor

UCB Pharma

Sponsor Class

Industry

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting

Phase 2

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosus

NCT04179032GlaxoSmithKline25

Completed

Phase 3

CORAL XT - Open-label Extension Trial of the CORAL TrialPainNeoplasmsChronic Pain

NCT02031432Tris Pharma, Inc.76

Completed

Phase 1

An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)Infertility

NCT00647933Organon and Co24

Terminated

Phase 3

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseWilson Disease

NCT05047523Alexion Pharmaceuticals, Inc.40

Recruiting

Phase 2

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusCerebral Intraventricular Hemorrhage

NCT06563817Beijing Tiantan Hospital53